08:42 AM EDT, 07/16/2025 (MT Newswires) -- Qualigen Therapeutics ( QLGN ) said Wednesday that it was granted patent protection in over 20 European countries for pancreatic and gastrointestinal cancer drug QN-302 during the first six months of the year.

The company also said it was granted similar patent coverage in China, India and Russia.

The drug was developed by researchers at the University College of London and was licensed by Qualigen, the biotechnology company said, adding that the patent covers QN-302 and its method of manufacture.

The expiration on the patents extends into 2040, the company said.

Shares of the company were up more than 87% in recent premarket activity.